Introduction
An adequate dietary supply of iron is essential both to maintain red blood cell production and for the normal function of a number of key metabolic enzymes. Body iron is maintained primarily by regulation of the absorption of dietary iron in the proximal small intestine (Sharp, Tandy, Yamaji, Tennant, Williams & Singh Srai, 2002; Sharp & Srai, 2007) . Dietary iron is found in two basic forms, as haem or non-haem, in the form of iron oxides, salts or chelates.
Non-haem iron is the predominant form in most diets, but the bioavailability of this form is relatively low (1-10%) (Sharp & Srai, 2007) . The uptake of dietary non-haem iron into the gastrointestinal (GI) tract requires protein-mediated transport, and two separate enterocyte pathways have been identified, namely the Divalent Metal Transporter-1 (DMT1) and the Integrin-Mobilferrin pathway (IMP) (Conrad & Umbreit, 2000; Conrad et al., 2000) . DMT1
requires the iron to be in the ferrous form (Fe 2+ ), and as a major proportion of dietary iron is in the ferric form (Fe 3+ ) it needs to be reduced prior to uptake by DMT1 in the enterocytes. Several mechanisms are potentially available to reduce non-haem iron into the ferrous form. The brush border of duodenal enterocytes and cultured intestinal cells possess ferric reductase enzyme activity (Dcytb) (Latunde-Dada, Van der Westhuizen, Vulpe, Anderson, Simpson & Mckie, 2002) , and overexpression of Dcytb in intestinal cells has been shown to stimulate iron uptake (Latunde-Dada, Simpson & Mckie, 2008) . Non-haem iron can also be reduced by dietary factors, the most important being ascorbate that can reduce ferric iron to the more absorbable ferrous form (Teucher, Olivares & Cori, 2004) . The presence of ascorbate has been previously shown to increase iron uptake in a dose-dependent fashion in vitro (Han, Failla, Hill, Morris & Smith, 1995; Kalgaonkar & Lonnerdal, 2008) and to increase the absorption of iron in human studies (Olivares, Pizarro, Pineda, Name, Hertrampf & Walter, 1997; Lopez & Martos, 2004; Moretti, Zimmermann, Wegmuller, Walczyk, Zeder & Hurrell, 2006) . Following reduction, the Fe 2+ becomes a substrate for DMT1 (Sharp & Srai, 2007) . In contrast to DMT1, the IMP pathway transports solely ferric iron, but not other metals of nutritional importance, and requires the chelation of ferric iron by mucins before interaction with 3-integrin and mobilferrin (Conrad & Umbreit, 2002; Sharp & Srai, 2007) .
The purpose of this study was to gain a better understanding of the mechanism by which ascorbate enhances the uptake of ferric iron into the small intestine, using the Caco-2 cell model of human small intestinal enterocytes (Yamaji, Tennant, Tandy, Williams, Singh Srai & Sharp, 2001) . We have used a kinetic approach and interpreted the results to show that ferric iron forms a complex with ascorbate, which is subsequently transported into the cells by a DMT1-independent mechanism.
Materials and methods

Cell culture
Caco-2 TC7 cells were maintained in 25-cm 2 plastic flasks. The cells were grown in Dulbecco's Modified Eagle Medium (DMEM) from GIBCO (Grand Island, NY), supplemented with 20% v/v foetal calf serum (GIBCO), 1% v/v non-essential amino acids (GIBCO), 1% antibiotic antimycotic (penicillin-steptomycin) solution (GIBCO) and 1% v/v L-glutamine (Biowhittaker Europe; Verviers, Belgium). The cells were maintained at 37 ºC in an incubator with 5% carbon dioxide (CO 2 ), 95% air atmosphere at constant 95% relative humidity, and the medium replaced every 2 days. For iron uptake experiments, the cells were seeded at a density of 40,000 cells/cm 2 in collagen-treated six-well plates (Costar Corp.; Cambridge, MA) and used at 21 days after seeding (Johnson, Yamaji, Tennant, Srai & Sharp, 2005) .
Iron uptake studies
Caco-2 cells were transferred to serum-free medium for 24 hours before the start of experiments.
The cells were washed by incubation with buffer (140 mM NaCl, 5 mM KCl, 1 mM NaH 2 PO 4, 10 mM MES, 0.5 mM of MgCl 2 , 1 mM CaCl 2 pH 6.0) for 2 minutes at 37 ºC. In order to measure iron uptake, 60 kBq of 55 Fe(II) were added to each culture well and incubated for 15 minutes at 37 ºC. Uptake was stopped by washing the cells three times with ice-cold buffer and the cells were solubilised in 1 ml of 200 mM NaOH overnight (4 ºC). Intracellular radioactivity was determined by scintillation counting.
The data was fitted to a hyperbolic equation by non-linear regression (SigmaPlot, Systat Software Inc. San Jose):
where [FeCl 3 ] is the concentration of substrate, V max is the calculated maximum velocity of the reaction and K m is the calculated Michaelis constant, an indicator of substrate affinity (Segel, 1975) .
Cell viability assay
To ensure that our iron and ascorbate treatments did not induce cytotoxicity which might in turn influence iron reduction and uptake, an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to determine cell viability. This assay measures the cleavage of MTT to a formazan derivative by mitochondrial enzymes and there is a linear relationship between the amount of formazan produced and the number of viable cells (Mosmann, 1983; Ferrari, Fornasiero & Isetta, 1990) . To each well of a 96-well culture plate was added 10 µl MTT reagent and the plate was incubated for 3-4 hours (37 ºC), before the addition of 100 µl DMSO per well to solubilise the cells. The absorbance of formazan product was determined at 570 nm.
Ferric reduction assay
The conversion of Fe 3+ to Fe 2+ in the absence or presence of ascorbate was measured spectrophotometrically by using a chromogenic ferrous iron chelator (bathophenanthrolinedisulfonic acid, BPDS) (Timmerman & Woods, 1999) . Uptake buffer (700 µl) containing various concentrations of Fe 3+ (0-30 µM) was added to a cell culture well containing 21-day post-confluence Caco-2 cultures and incubated for 15 minutes (37 ºC). The buffer was collected (4 ºC) and 500 µl of 2 mM BPDS added before incubation for 1 hour at 37
ºC. The concentration of Fe(II)-BPDS complex was measured at 534 nm, using a FeCl 2 standard curve.
Statistics and data analysis
Kinetic parameters were determined by fitting the data to a hyperbolic curve by non-linear regression (Prism 5 for Windows, GraphPad Software Inc.). Two-way ANOVA with Bonferroni post-test was used to determine statistical significance (Prism 5 for Windows, GraphPad Software Inc.).
Results and Discussion
The aim of this study was to kinetically investigate the uptake of non-haem iron by Caco-2 cells, and its promotion by ascorbate. The uptake of FeCl 3 across the apical membrane of Caco-2 cells has been well-documented to be a protein-mediated process, with several proteins capable of playing the role of iron transporter (Garrick et al., 2006) . This observation was confirmed by the saturable, hyperbolic nature of 55 Fe(II) uptake (Fig. 1) , with a calculated V max of 304 pmol/h and K m of 13.2 µM. A previous study showed that ferrous iron uptake by Caco-2 cells was also saturable, with a K m of 7 µM (Linder, Moriya, Whon, Kassa & Gilley, 2006) , a value that is essentially identical to that obtained in our study (Fig. 1 ). It has previously been shown that the reduction of ferric iron is required for uptake into Caco-2 cells (Han et al., 1995) , and a potent enhancer of iron uptake is ascorbate (vitamin C) (Teucher, Olivares & Cori, 2004) , which is capable of reducing ferric to ferrous iron (Johnson, Yamaji, Tennant, Srai & Sharp, 2005) . In our studies the presence of ascorbate in the cell culture media significantly increased the rate of iron uptake in a concentration-dependent manner ( Fig. 2 ; Table 1) , and had no effect on cell viability at concentrations up to 30 µM ascorbate (data not shown).
The process by which ascorbate increases iron uptake has previously been ascribed to the reductive properties of ascorbate that increase the conversion of ferric to ferrous iron (Teucher et al., 2004) , the latter then being a substrate for the membrane transporter DMT1 that is specific for ferrous iron (Sharp et al., 2002; Sharp & Srai, 2007) . Indeed, it is believed that ascorbate secreted in gastric juice is present to reduce dietary iron, preventing the formation of nonbioavailable ferric chelates (Atanasov, Li, Bjarnason, Tzatchev & Simpson, 2005) . If the reduction of ferric iron by ascorbate, or any other dietary reductant, was obligatory for the intestinal uptake of dietary ferric iron, then we should not observe a protein-mediated ferric iron uptake process. As shown here ( Figs. 1 and 2 ) and in other studies (Han et al., 1995) , this is clearly not the case, as the Caco-2 cells take up a low, basal level of iron in the absence of ascorbate. One proposed mechanism to explain this observation involves the presence of a membrane-bound ferric reductase, Dcytb, that can catalyse the reduction of ferric iron in the absence of ascorbate, or other dietary reducing agents, to stimulate iron reduction and uptake into Caco-2 cells (Yamaji et al., 2001; Latunde-Dada et al., 2002; Sharp & Srai, 2007; LatundeDada et al., 2008) . However, the endogenous expression of Dcytb in Caco-2 cells is very low (Latunde-Dada et al., 2008 ).
An alternative proposal is that ferric iron reduction is not essential and that there are separate pathways for the uptake of ferric and ferrous iron (Han et al., 1995) . In order to separate the processes of reduction and increased uptake, both of which could potentially be catalysed by ascorbate, we determined ferric iron uptake rates and reduction under identical conditions (Fig. 3) . Both iron uptake (Fig. 3A) and ferric iron reduction (Fig. 3B) were significantly increased in the presence of ascorbate. We surmised that if the promoting effect of ascorbate on iron uptake was due only to its role as a reductant, then a comparison of 55 Fe uptake vs. ferrous reduction should show a direct, linear correlation with a slope equal to one. This was observed in the absence of ascorbate, but there was a significant difference in the presence of ascorbate (Fig. 3C ). This observation implies that a process distinct from iron reduction may explain the promoting effect of ascorbate and therefore a kinetic approach was used to determine the mechanism of rate enhancement observed with ascorbate. (Fig. 4) (Segel, 1975) , with activation of 55 Fe uptake by ascorbate being saturable, as indicated by the finite V max obtained (Fig. 4 inset) . These observations are characteristic of a non-essential activator process (Segel, 1975) and indicate that ascorbate forms a complex with ferric iron that is then taken up into the Caco-2 cells. This finding implies that ascorbate functions as a chelating agent of ferric iron and suggests that an iron-ascorbate complex enters the cells directly, although we cannot determine whether the iron in this complex is in the Fe 3+ or Fe 2+ form.
To further explore the kinetics of ascorbate-induced iron uptake we undertook similar experiments in the presence of a known inhibitor. Previous studies have shown that Zn 2+ inhibits the intestinal uptake of iron (Yamaji et al., 2001; Han et al., 1995; Solomons, Pineda, Viteri & Sandstead, 1983; Arredondo, Martinez, Nunez, Ruz & Olivares, 2006; Conrad, Umbreit, Moore, Uzel & Berry, 1994) , but its effects are not mediated through DMT1 (Tandy et al., 2000; Garrick et al., 2003; Mackenzie, Takanaga, Hubert, Rolfs & Hediger, 2007 our findings would imply that DMT1 is not involved in the uptake of the iron-ascorbate complex.
Thus, a different transporter system must be involved in the uptake of the iron-ascorbate complex and one possibility is that this complex interacts with IMP-3-intergrin-mobilferrin pathway, in a manner similar to that of Fe 3+ -mucin transport complex (Sharp & Srai, 2007) , while other options include Zip14, a transporter of both iron and zinc in the duodenum, and the SVCT1 ascorbate transporter (Liuzzi, Aydemir, Nam, Knutson & Cousins, 2006; Wilson, 2005) .
In conclusion, this investigation provides evidence that ascorbate, in addition to its wellcharacterised reduction of ferric iron to provide a bioavailable supply of ferrous iron to DMT1, also enhances directly the uptake of ferric iron into Caco-2 cells through the formation of an iron-ascorbate complex. DMT1 is not involved in the uptake of the iron-ascorbate complex and further work is required to identify the transporter system involved in the uptake of the ironascorbate complex into intestinal enterocytes. 
